ASTRAZENECA PHARMA IND LT (ASTRAZEN) financials

ASTRAZENECA PHARMA IND LT (ASTRAZEN) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

Market Cap: ₹14,926Cr.
Current Price: ₹5,970
Stock P/E: 86.0
ROE: 23.3%
ROCE: 29.3%
Book Value: ₹349
Dividend Yield: 0.60%
52W High / Low: ₹9,850/5,640

In Jun 2026, ASTRAZENECA PHARMA IND LT (ASTRAZEN) reported sales ₹683 Cr and net profit ₹38 Cr.

Annual TTM: sales ₹2,432 Cr, net profit ₹170 Cr.

Shareholding: Promoters 75.00% (Sep 2026), FIIs 2.64% (Sep 2026), DIIs 7.09% (Sep 2026), Public 15.27% (Sep 2026), No. of Shareholders 30,408% (Sep 2026).

ASTRAZEN quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	408	440	480	526	559	612	579	683
Expenses	355	363	394	445	484	567	518	634
Operating Profit	53	77	86	81	75	45	61	49
OPM %	13%	17%	18%	15%	13%	7%	11%	7%
Other Income	8	-26	10	11	1	7	5	9
Interest	0	0	1	1	1	1	2	2
Depreciation	9	9	18	17	3	4	6	5
Profit before tax	51	42	78	75	73	47	58	51
Tax %	25%	27%	26%	25%	26%	30%	23%	25%
Net Profit	38	31	58	56	54	33	45	38
EPS in Rs	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17
Raw PDF	—	—	—	—	—	—	—	—

ASTRAZEN profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	832	814	806	1,003	1,296	1,716	2,276	2,432
Expenses	711	678	719	838	1,111	1,462	2,014	2,202
Operating Profit	121	135	86	165	184	254	262	230
OPM %	15%	17%	11%	16%	14%	15%	12%	9%
Other Income	13	13	15	-14	51	-56	23	21
Interest	1	1	1	1	1	1	4	6
Depreciation	19	20	17	16	15	40	29	17
Profit before tax	114	127	83	134	220	156	252	228
Tax %	37%	27%	26%	26%	26%	26%	26%	—
Net Profit	72	93	62	99	162	116	188	170
EPS in Rs	28.88	37.32	24.64	39.72	64.60	46.30	75.01	67.85
Dividend Payout %	3%	5%	41%	40%	37%	69%	48%	—

ASTRAZEN balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5	5	5	5	5	5	5	5
Reserves	296	359	451	506	584	707	765	868
Borrowings	0	12	12	9	7	5	36	111
Other Liabilities	261	330	306	337	389	362	712	1,006
Total Liabilities	562	706	775	857	985	1,078	1,518	1,989
Fixed Assets	75	72	81	74	69	67	64	117
CWIP	7	24	4	2	1	0	0	0
Investments	0	0	0	0	0	0	0	0
Other Assets	480	611	690	780	915	1,011	1,454	1,872
Total Assets	562	706	775	857	985	1,078	1,518	1,989

ASTRAZEN cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	55	87	105	101	58	28	65	-15
Cash from Investing Activity	4	-171	173	5	18	22	31	19
Cash from Financing Activity	0	-6	-9	-9	-24	-44	-66	-92
Net Cash Flow	59	-90	269	96	52	5	31	-88
Free Cash Flow	37	74	99	94	53	18	64	-18
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	126%	100%	101%	146%	60%	46%	51%	26%

ASTRAZEN shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
FIIs	2.92%	2.89%	3.03%	2.74%	2.71%	2.78%	2.68%	2.64%
DIIs	5.21%	4.65%	4.55%	5.26%	5.55%	5.79%	6.08%	7.09%
Public	16.85%	17.45%	17.41%	17.00%	16.73%	16.42%	16.24%	15.27%
No. of Shareholders	27,322	32,466	34,378	32,914	31,551	29,007	29,338	30,408

ASTRAZEN key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	40	37	38	39	39	43	39	34
Inventory Days	186	197	198	164	193	140	208	272
Days Payable	266	251	221	223	231	121	173	207
Cash Conversion Cycle	-39	-17	15	-20	1	62	74	99
Working Capital Days	-14	-16	-17	-34	-18	20	22	50
ROCE %	27%	34%	30%	16%	31%	31%	33%	29%

ASTRAZENUpdated 18 Oct 2026, 5:22

Astrazeneca Pharma Ind Lt

ASTRAZENUpdated 18 Oct 2026, 5:22

Market Cap

₹14,926Cr.

Current Price

₹5,970

High / Low

₹9,850/5,640

Stock P/E

86.0

ROE23.3%

ROCE29.3%

Book Value₹349

Face Value₹2.00

Dividend Yield0.60%

About

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	295	0	228	8	4	71	25	54	21.54
Sep 2023	311	0	258	25	4	73	29	52	20.95
Dec 2023	306	1	291	10	4	20	23	16	6.32
Mar 2024	383	0	334	9	4	54	27	39	15.79
Jun 2024	388	0	349	-49	4	-15	-22	-12	-4.72
Sep 2024	408	0	355	8	9	51	25	38	15.37
Dec 2024	440	0	363	-26	9	42	27	31	12.34
Mar 2025	480	1	394	10	18	78	26	58	23.3
Jun 2025	526	1	445	11	17	75	25	56	22.33
Sep 2025	559	1	484	1	3	73	26	54	21.69
Dec 2025	612	1	567	7	4	47	30	33	13.04
Mar 2026	579	2	518	5	6	58	23	45	17.95
Jun 2026	683	2	634	9	5	51	25	38	15.17

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	517	0	528	6	15	-21	0	-21	-8.34
Mar 2016	564	0	547	7	17	6	9	5	2.1
Mar 2017	544	0	506	14	16	36	44	20	8.02
Mar 2018	571	0	525	12	15	44	41	26	10.36
Mar 2019	728	0	657	16	15	73	25	54	21.78
Mar 2020	832	1	711	13	19	114	37	72	28.88
Mar 2021	814	1	678	13	20	127	27	93	37.32
Mar 2022	806	1	719	15	17	83	26	62	24.64
Mar 2023	1003	1	838	-14	16	134	26	99	39.72
Mar 2024	1296	1	1111	51	15	220	26	162	64.6
Mar 2025	1716	1	1462	-56	40	156	26	116	46.3
Mar 2026	2276	4	2014	23	29	252	26	188	75.01
TTM	2432	6	2202	21	17	228	—	170	67.85

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	75%
FIIs	2.64%
DIIs	7.09%
Public	15.27%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	75%	2.66%	2.76%	19.57%
Mar 2024	75%	2.73%	3.77%	18.5%
Jun 2024	75%	2.79%	4.99%	17.21%
Sep 2024	75%	2.9%	5.08%	17.02%
Dec 2024	75%	2.92%	5.21%	16.85%
Mar 2025	75%	2.89%	4.65%	17.45%
Jun 2025	75%	3.03%	4.55%	17.41%
Sep 2025	75%	2.74%	5.26%	17%
Dec 2025	75%	2.71%	5.55%	16.73%
Mar 2026	75%	2.78%	5.79%	16.42%
Jun 2026	75%	2.68%	6.08%	16.24%
Sep 2026	75%	2.64%	7.09%	15.27%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Other Assets	Total Assets
Mar 2015	5	146	0	261	412	101	12	298	412
Mar 2016	5	151	0	247	403	97	6	299	403
Mar 2017	5	218	0	193	415	87	5	324	415
Mar 2018	5	242	0	214	461	75	4	382	461
Mar 2019	5	296	0	261	562	75	7	480	562
Mar 2020	5	359	12	330	706	72	24	611	706
Mar 2021	5	451	12	306	775	81	4	690	775
Mar 2022	5	506	9	337	857	74	2	780	857
Mar 2023	5	584	7	389	985	69	1	915	985
Mar 2024	5	707	5	362	1078	67	0	1011	1078
Mar 2025	5	765	36	712	1518	64	0	1454	1518
Mar 2026	5	868	111	1006	1989	117	0	1872	1989

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-46	-19	0	-64
Mar 2016	57	-4	-1	53
Mar 2017	38	0	0	38
Mar 2018	9	-9	0	-1
Mar 2019	55	4	0	59
Mar 2020	87	-171	-6	-90
Mar 2021	105	173	-9	269
Mar 2022	101	5	-9	96
Mar 2023	58	18	-24	52
Mar 2024	28	22	-44	5
Mar 2025	65	31	-66	31
Mar 2026	-15	19	-92	-88

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	30	54	29	35	40	37	38	39	39	43	39	34
Inventory Days	157	141	121	229	186	197	198	164	193	140	208	272
Days Payable	203	174	184	257	266	251	221	223	231	121	173	207
Cash Conversion Cycle	-16	21	-34	7	-39	-17	15	-20	1	62	74	99
Working Capital Days	-15	-28	-36	-8	-14	-16	-17	-34	-18	20	22	50
ROCE %	-13%	4%	15%	19%	27%	34%	30%	16%	31%	31%	33%	29%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of ASTRAZENECA PHARMA IND LT (ASTRAZEN)?

The reported market capitalisation for ASTRAZENECA PHARMA IND LT (ASTRAZEN) is ₹14,926Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of ASTRAZEN?

The current price shown for ASTRAZENECA PHARMA IND LT (ASTRAZEN) on Fincrux is ₹5,970 with a 52-week high/low of ₹9,850/5,640.

What is the P/E ratio of ASTRAZENECA PHARMA IND LT (ASTRAZEN)?

The stock P/E for ASTRAZENECA PHARMA IND LT (ASTRAZEN) is 86.0 on Fincrux, with ROE at 23.3% and ROCE at 29.3%.

What were ASTRAZEN latest quarterly results?

For Jun 2026, ASTRAZENECA PHARMA IND LT (ASTRAZEN) reported sales ₹683 Cr and net profit ₹38 Cr (figures in ₹ crore unless noted).

What are ASTRAZEN annual sales and net profit?

For TTM, ASTRAZENECA PHARMA IND LT (ASTRAZEN) shows sales of ₹2,432 Cr and net profit of ₹170 Cr on the Fincrux profit & loss statement.

Who owns ASTRAZENECA PHARMA IND LT (ASTRAZEN)?

Latest shareholding for ASTRAZENECA PHARMA IND LT (ASTRAZEN) on Fincrux: Promoters 75.00% (Sep 2026), FIIs 2.64% (Sep 2026), DIIs 7.09% (Sep 2026), Public 15.27% (Sep 2026), No. of Shareholders 30,408% (Sep 2026).

Where can I find ASTRAZENECA PHARMA IND LT (ASTRAZEN) financials?

ASTRAZENECA PHARMA IND LT (ASTRAZEN) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show ASTRAZEN balance sheet and cash flow?

Yes. The ASTRAZENECA PHARMA IND LT (ASTRAZEN) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 5:22